Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
121.4 USD | -0.07% | -1.08% | +11.39% |
Mar. 15 | Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time | RE |
Mar. 15 | Merck: promising new results for Keytruda | CF |
Business Summary
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Number of employees: 71,000
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
89.1
%
| 52,005 | 87.7 % | 53,583 | 89.1 % | +3.03% |
Animal Health
9.4
%
| 5,550 | 9.4 % | 5,625 | 9.4 % | +1.35% |
Other
1.5
%
| 1,728 | 2.9 % | 907 | 1.5 % | -47.51% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
47.4
%
| 27,206 | 45.9 % | 28,480 | 47.4 % | +4.68% |
Europe, Middle East and Africa
22.0
%
| 14,493 | 24.4 % | 13,254 | 22.0 % | -8.55% |
China
11.3
%
| 5,191 | 8.8 % | 6,802 | 11.3 % | +31.03% |
Asia Pacific
5.4
%
| 3,614 | 6.1 % | 3,225 | 5.4 % | -10.76% |
Japan
5.3
%
| 3,629 | 6.1 % | 3,164 | 5.3 % | -12.81% |
Latin America
5.1
%
| 2,582 | 4.4 % | 3,086 | 5.1 % | +19.52% |
Other
3.5
%
| 2,568 | 4.3 % | 2,104 | 3.5 % | -18.07% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
Peter Dannenbaum
IRC | Investor Relations Contact | - | 17-06-30 |
Joseph Romanelli
IRC | Investor Relations Contact | 50 | 95-12-31 |
Johanna Herrmann
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | 20-12-31 | |
Andre Musto
PRN | Corporate Officer/Principal | - | 14-06-30 |
Carol Bowden
PRN | Corporate Officer/Principal | - | 14-03-31 |
James Matteucci
PRN | Corporate Officer/Principal | - | 02-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 66 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
Patricia Russo
BRD | Director/Board Member | 71 | 95-08-31 |
Peter Wendell
BRD | Director/Board Member | 73 | 03-09-22 |
Director/Board Member | 69 | 20-05-25 | |
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
Douglas Baker
BRD | Director/Board Member | 65 | 22-05-23 |
Stephen Mayo
BRD | Director/Board Member | 62 | 21-03-14 |
Kathy Warden
BRD | Director/Board Member | 52 | 20-03-15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,578,114,121 | 2,531,706,123 ( 70.76 %) | 1,045,470,249 ( 29.22 %) | 70.76 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
13,443,693 | 10.62% | 185,973,865 $ | |
1,739,768 | 5.21% | 23,017,131 $ | |
NGM BIOPHARMACEUTICALS, INC. 15.66% | 12,955,016 | 15.66% | 19,691,624 $ |
XILIO THERAPEUTICS, INC. 5.39% | 1,483,414 | 5.39% | 1,051,741 $ |
EVAXION BIOTECH A/S 12.13% | 2,297,884 | 12.13% | 827,238 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Pharmaceuticals: Major
| |
Organon (India) Pvt Ltd.
Organon (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology Organon India Pvt Ltd. manufactures and distribution of pharmaceutical preparations. The company is headquartered in Mumbai, India. |
Pharmaceuticals: Major
|
Dashtag
Dashtag Financial ConglomeratesFinance Founded in 1906, Dashtag is a part of Organon & Co. and operates an investment holding British company. The private company is based in Hoddesdon, UK. |
Financial Conglomerates
|
MSD Sharp & Dohme GmbH
MSD Sharp & Dohme GmbH Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD Sharp & Dohme GmbH develops and manufactures pharmaceutical products. The private company is based in Haar, Germany. The German company was founded in 1891. Chantal Friebertshäuser has been the CEO of the company since 2007. |
Pharmaceuticals: Major
|
Merck Holdings, Inc.
| |
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ. |
Pharmaceuticals: Major
|
Intervet India Pvt Ltd.
| |
Essex Chemie AG
| |
Merck Sharp & Dohme Finance Europe Ltd.
Merck Sharp & Dohme Finance Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 1993, Merck Sharp & Dohme Finance Europe Ltd. is a British company that provides business support services. Part of Merck & Co., Inc., the private company is based in Hoddesdon, UK. |
Miscellaneous Commercial Services
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.39% | 308B | |
+30.83% | 679B | |
+30.96% | 589B | |
+0.01% | 381B | |
+15.18% | 314B | |
+0.78% | 212B | |
-6.09% | 210B | |
-2.92% | 203B | |
-3.72% | 158B | |
-5.94% | 144B |
- Stock
- Equities
- Stock Merck & Co., Inc. - Nyse
- Company Merck & Co., Inc.